ArticleMultiple sclerosis journal - experimental, translational and clinical
Cortico-hippocampal molecular characterization in rat model of multiple sclerosis: Neuroprotective mechanisms of
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current multiple sclerosis management primarily targets symptom alleviation and immune modulation, with limited success in halting progression or achieving sustained remission. Consequently, the development of novel therapeutic strategies targeting the underlying mechanisms of multiple sclerosis (MS) remains a critical area of research. Objectives: This study investigated the putative neuroprotective properties of Methods: Twenty-four adult male Wistar rats were divided into four groups: Group A (Control) received normal mash feed; Group B received 0.2% cuprizone diet; Group C received 5 ml/kg NSO, while Group D received 0.2% cuprizone diet and 5 ml/kg NSO. After 35 days, rats were tested for memory and behaviour (Y-maze, Morris water maze, open-field test). Rats were euthanized, brains were excised then examined for myelin integrity, oligodendrocyte loss, and microglial activation using immunohistochemistry (antibodies: myelin basic protein, oligodendrocyte transcription factor, ionized calcium-binding adaptor molecule 1). Results: Cuprizone exposure resulted in impaired memory function, reduced exploratory behaviour, and increased anxiety-like behaviours. Treatment with NSO mitigated these behavioural deficits. Additionally, NSO treatment reduced microglial activation and preserved myelin integrity. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.